Table I.
Open in new tab

Parent-Report Questionnaire Clinical Cutoffs

ScaleN (%)
PHQ-9
 None/minimal (0–4)41 (25.9)
 Mild (5–9)67 (42.4)
 Moderate (10–14)26 (16.5)
 Severe (15+)24 (15.2)
GAD-7
 None/minimal (0–4)31 (19.6)
 Mild (5–9)74 (46.8)
 Moderate (10–14)39 (24.7)
 Severe (15+)0 (0.0)
IES-R
 No indications of PTSD67 (42.4)
 PTSD clinical concern (>24)81 (51.4)
CRIES-13
 No indications of PTSD131 (82.9)
 Probable PTSD (>30)25 (15.8)
PSC total
 None/minimal130 (82.3)
 Impairment (>28)28 (17.7)
PSC internalizing symptoms
 None/minimal126 (79.7)
 Clinical concern (>5)32 (20.3)
PSC inattention symptoms
 None/minimal129 (81.6)
 Clinical concern (> 7)29 (18.4)
PSC externalizing symptoms
 None/minimal129 (86.0)
 Clinical concern (>7)29 (18.4)
COVID impact
 Not at all severe (0–5)23 (15.1)
 Somewhat severe (>5–15)43 (28.3)
 Severe (>15–25)69 (45.4)
 Extremely severe (>25)17 (11.2)
ScaleN (%)
PHQ-9
 None/minimal (0–4)41 (25.9)
 Mild (5–9)67 (42.4)
 Moderate (10–14)26 (16.5)
 Severe (15+)24 (15.2)
GAD-7
 None/minimal (0–4)31 (19.6)
 Mild (5–9)74 (46.8)
 Moderate (10–14)39 (24.7)
 Severe (15+)0 (0.0)
IES-R
 No indications of PTSD67 (42.4)
 PTSD clinical concern (>24)81 (51.4)
CRIES-13
 No indications of PTSD131 (82.9)
 Probable PTSD (>30)25 (15.8)
PSC total
 None/minimal130 (82.3)
 Impairment (>28)28 (17.7)
PSC internalizing symptoms
 None/minimal126 (79.7)
 Clinical concern (>5)32 (20.3)
PSC inattention symptoms
 None/minimal129 (81.6)
 Clinical concern (> 7)29 (18.4)
PSC externalizing symptoms
 None/minimal129 (86.0)
 Clinical concern (>7)29 (18.4)
COVID impact
 Not at all severe (0–5)23 (15.1)
 Somewhat severe (>5–15)43 (28.3)
 Severe (>15–25)69 (45.4)
 Extremely severe (>25)17 (11.2)
Table I.
Open in new tab

Parent-Report Questionnaire Clinical Cutoffs

ScaleN (%)
PHQ-9
 None/minimal (0–4)41 (25.9)
 Mild (5–9)67 (42.4)
 Moderate (10–14)26 (16.5)
 Severe (15+)24 (15.2)
GAD-7
 None/minimal (0–4)31 (19.6)
 Mild (5–9)74 (46.8)
 Moderate (10–14)39 (24.7)
 Severe (15+)0 (0.0)
IES-R
 No indications of PTSD67 (42.4)
 PTSD clinical concern (>24)81 (51.4)
CRIES-13
 No indications of PTSD131 (82.9)
 Probable PTSD (>30)25 (15.8)
PSC total
 None/minimal130 (82.3)
 Impairment (>28)28 (17.7)
PSC internalizing symptoms
 None/minimal126 (79.7)
 Clinical concern (>5)32 (20.3)
PSC inattention symptoms
 None/minimal129 (81.6)
 Clinical concern (> 7)29 (18.4)
PSC externalizing symptoms
 None/minimal129 (86.0)
 Clinical concern (>7)29 (18.4)
COVID impact
 Not at all severe (0–5)23 (15.1)
 Somewhat severe (>5–15)43 (28.3)
 Severe (>15–25)69 (45.4)
 Extremely severe (>25)17 (11.2)
ScaleN (%)
PHQ-9
 None/minimal (0–4)41 (25.9)
 Mild (5–9)67 (42.4)
 Moderate (10–14)26 (16.5)
 Severe (15+)24 (15.2)
GAD-7
 None/minimal (0–4)31 (19.6)
 Mild (5–9)74 (46.8)
 Moderate (10–14)39 (24.7)
 Severe (15+)0 (0.0)
IES-R
 No indications of PTSD67 (42.4)
 PTSD clinical concern (>24)81 (51.4)
CRIES-13
 No indications of PTSD131 (82.9)
 Probable PTSD (>30)25 (15.8)
PSC total
 None/minimal130 (82.3)
 Impairment (>28)28 (17.7)
PSC internalizing symptoms
 None/minimal126 (79.7)
 Clinical concern (>5)32 (20.3)
PSC inattention symptoms
 None/minimal129 (81.6)
 Clinical concern (> 7)29 (18.4)
PSC externalizing symptoms
 None/minimal129 (86.0)
 Clinical concern (>7)29 (18.4)
COVID impact
 Not at all severe (0–5)23 (15.1)
 Somewhat severe (>5–15)43 (28.3)
 Severe (>15–25)69 (45.4)
 Extremely severe (>25)17 (11.2)
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close